- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe asthma Bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 454KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 84KB)
Tiotropium – November 2024
Tiotropium; Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (2 x 60 actuations), pack of 2; Spiriva® Respimat®
Last updated
30 May 2025